Berbamine, a novel nuclear factor B inhibitor, inhibits growth and induces apoptosis in human myeloma cells

Acta Pharmacologica Sinica

Volumn 30, Issue 12, 2009, Pages 1659-1665

  Liang, Yun ^a   Xu, Rong Zhen ^a   Zhang, Lei ^a   Zhao, Xiao Ying ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Berbamine; Multiple myeloma; Nuclear factor kappa B

Indexed keywords

ACTIN; ARSENIC TRIOXIDE; BERBAMINE; CYCLIN D1; DEXAMETHASONE; DOXORUBICIN; HISTONE H1; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; SURVIVIN; SYNAPSIN II; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MICROSCOPY; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TARGET CELL; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BENZYLISOQUINOLINES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DEXAMETHASONE; DOXORUBICIN; G1 PHASE; HUMANS; I-KAPPA B KINASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIPLE MYELOMA; NF-KAPPA B; NUCLEAR PROTEINS; OXIDES; PLASMA CELLS; SIGNAL TRANSDUCTION;

EID: 74949124948     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.167     Document Type: Article

References (20)

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 15-17
2. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927-37.
3. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607-18.
4. Ge MZ, Liu X, Zhang Y. An experiment on immune protection unction of berbamine in mice injury by irradiation. Immunol J 1998; 4: 238-40.
5. Liu X, Zhou ZR. The effect of berbamine on the immunoregulation of BALB/c mice. J China Med Univ 1996; 25: 229-31.
6. Xu RZ, Dong QH, Yu YZ, Zhao XY, Gan XX, Wu D, et al. Berbanine: A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res 2006; 30: 17-23.
7. Zhao XY, He ZW, Wu D, Xu RZ. Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivingmediated pathway. Chin Med J 2007; 120: 802-6.
8. Wei YL, Xu L, Liang Y, Xu XH, Zhao XY. Berbanine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacol Sin 2009; 30: 451-7.
9. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-βB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-47.
10. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF- ?B activity by thalidomide through suppression of I?B kinase activity. J Biol Chem 2001; 276: 22382-7.
11. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res 2001; 61: 3071-6.
12. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93: 3044-52.
13. Baldwin AS Jr. The NF-βB and I?B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-81.
14. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003; 22: 8961-82.
15. Orlowski RZ, Baldwin AS Jr. NF-KappaB as a therapeutic target in cancer. Trends Mol Med 2002; 8: 385-9.
16. San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006; 11: 51-61. (Pubitemid 43152686)
17. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-3120
18. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, Abbott DW. I?B Kinase ? phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-βB Pathway. Mol Cell Biol 2007; 27: 7451-61.
19. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001; 107: 3-6.
20. Li J, Peet GW, Balzarano D, Li X, Massa P, Barton RW, et al. Novel NEMO/I?B kinase and NF-βB target genes at the Pre-B to immature B cell transition. J Biol Chem 2001; 276: 18579-90.